Literature DB >> 12900475

COX-2 inhibitors and type 4 error.

Michal R Pijak, Frantisek Gazdik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12900475      PMCID： PMC167118     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  Aspirin use may change cost-effectiveness of COX-2 inhibitors.

Authors:  A Simon Pickard; Glen T Schumock
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

2.  Seeking disclosure.

Authors:  Walter P Maksymowych
Journal:  CMAJ       Date:  2003-04-15       Impact factor: 8.262

3.  Type 3 and type 4 errors in the statistical evaluation of clinical trials.

Authors:  E D Robin; N J Lewiston
Journal:  Chest       Date:  1990-08       Impact factor: 9.410

4.  Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Authors:  A Whelton; J G Fort; J A Puma; D Normandin; A E Bello; K M Verburg
Journal:  Am J Ther       Date:  2001 Mar-Apr       Impact factor: 2.688

5.  Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

Authors:  Alise S Reicin; Deborah Shapiro; Rhoda S Sperling; Eliav Barr; Qinfen Yu
Journal:  Am J Cardiol       Date:  2002-01-15       Impact factor: 2.778

Review 6.  The double-edged sword of COX-2 selective NSAIDs.

Authors:  James M Wright
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

Review 7.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

8.  A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.

Authors:  S Z Zhao; M W Reynolds; J Lejkowith; A Whelton; F M Arellano
Journal:  Clin Ther       Date:  2001-09       Impact factor: 3.393

9.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

Authors:  William B White; Gerald Faich; Andrew Whelton; Clement Maurath; Nancy J Ridge; Kenneth M Verburg; G Steven Geis; James B Lefkowith
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

10.  What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262
  10 in total
  1 in total

1.  Coxibs and cardiovascular risk.

Authors:  Michal R Pijak; Igor Huzicka; Frantisek Gazdik
Journal:  CMAJ       Date:  2005-10-11       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.